Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Osteocalcin Monoclonal Antibody (OCG2)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA125584
Description
MA1-25584 will not react with mouse.
Osteocalcin belongs to the osteocalcin/matrix Gla-protein family and constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium. Gamma-carboxyglutamate residues are formed by vitamin K dependent carboxylation. These residues are essential for the binding of calcium.
Specifications
Osteocalcin | |
Monoclonal | |
2 mg/mL | |
PBS with 1% BSA and no preservative; pH 7.4 | |
P02818, P02820 | |
BGLAP | |
Full length bovine protein. | |
50 μg | |
Primary | |
Human, Bovine | |
Antibody | |
IgG1 |
ELISA, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot | |
OCG2 | |
Unconjugated | |
BGLAP | |
Bglap; Bglap1; Bglap2; BGP; Bgpr; Bgpra; bone gamma carboxyglutamate protein; bone gamma carboxyglutamate protein 1; bone gamma-carboxyglutamate (gla) protein; bone gamma-carboxyglutamate (gla) protein (osteocalcin); bone gamma-carboxyglutamate protein; bone gamma-carboxyglutamate protein 2; bone gamma-carboxyglutamate protein osteocalcin; bone gamma-carboxyglutamate; BGLAP; bone gamma-carboxyglutamic acid (Gla) protein (osteocalcin); bone Gla protein; bone gla protein BGP; bone Gla-protein; gamma-carbooxyglutamate (gla) protein; Gamma-carboxyglutamic acid-containing protein; GLA; Gla protein precusor; mOC-A; OC; OCN; OG1; Osteocalcin; PMF1; RP11-54H19.5; unnamed protein product | |
Mouse | |
Affinity chromatography | |
RUO | |
281646, 632 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Safety and Handling
WARNING: Reproductive Harm - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction